Please assess the completion status of the following clinical trial:

Trial Title: Sublingual Immunotherapy for Food Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic, reproducible symptoms following meals.~2. Multiple food allergies where dietary avoidance is nearly impossible.~3. Patients age 4 and older.~4. Testing to verify food allergies is positive.~Exclusion Criteria:~1. History of anaphylaxis, angioedema, asthma, or life-endangering reactions to certain food products.~2. Children under the age of 4.~3. Previous attempts to treat food allergy (subcutaneous injections).~4. General medical condition that precludes elective therapy (including pregnancy).~5. Inability to follow food allergy SLIT regimen.~6. Autoimmune Disease.~7. Chronic use of steroids.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Food Drops (Type: NO_INTERVENTION): The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
- Food Drops (Type: ACTIVE_COMPARATOR): Group 2 (intervention group) will receive sublingual immunotherapy (escalation followed by maintenance) with vials containing glycerin and the previously diagnosed food allergens (peptides).

Based on this trial design, predict the completion outcome and termination type (if applicable).